Zobrazeno 1 - 10
of 455
pro vyhledávání: '"Sarah A. Gilbert"'
Autor:
Katie Shilton, Emanuel Moss, Sarah A. Gilbert, Matthew J. Bietz, Casey Fiesler, Jacob Metcalf, Jessica Vitak, Michael Zimmer
Publikováno v:
Big Data & Society, Vol 8 (2021)
Frequent public uproar over forms of data science that rely on information about people demonstrates the challenges of defining and demonstrating trustworthy digital data research practices. This paper reviews problems of trustworthiness in what we t
Externí odkaz:
https://doaj.org/article/91ac7e8b5e9848859949e91c4d4e8dd0
Autor:
Eleni Vatzia, Basudev Paudyal, Barbara Dema, Brigid Veronica Carr, Ehsan Sedaghat-Rostami, Simon Gubbins, Bhawna Sharma, Elliot Moorhouse, Susan Morris, Marta Ulaszewska, Ronan MacLoughlin, Francisco J. Salguero, Sarah C. Gilbert, Elma Tchilian
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-15 (2024)
Abstract Current influenza vaccines are strain-specific and require frequent updates to combat new strains, making a broadly protective influenza vaccine (BPIV) highly desirable. A promising strategy is to induce T-cell responses against internal pro
Externí odkaz:
https://doaj.org/article/ca1c422f5b0b422cbcff2e60d8a41134
Autor:
Ruth E. Drury, Susana Camara, Irina Chelysheva, Sagida Bibi, Katherine Sanders, Salle Felle, Katherine Emary, Daniel Phillips, Merryn Voysey, Daniela M. Ferreira, Paul Klenerman, Sarah C. Gilbert, Teresa Lambe, Andrew J. Pollard, Daniel O’Connor
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)
Abstract The immune mechanisms mediating COVID-19 vaccine attenuation of COVID-19 remain undescribed. We conducted comprehensive analyses detailing immune responses to SARS-CoV-2 virus in blood post-vaccination with ChAdOx1 nCoV-19 or a placebo. Samp
Externí odkaz:
https://doaj.org/article/a631bf1fd8ab45f689a2d26cb54715f6
Autor:
Edmund G.-T. Wee, Sarah Kempster, Deborah Ferguson, Joanna Hall, Claire Ham, Susan Morris, Alison Crook, Sarah C. Gilbert, Bette Korber, Neil Almond, Tomáš Hanke
Publikováno v:
Vaccines, Vol 12, Iss 9, p 965 (2024)
During the COVID-19 pandemic, antibody-based vaccines targeting the SARS-CoV-2 spike glycoprotein were the focus for development because neutralizing antibodies were associated with protection against the SARS-CoV-2 infection pre-clinically and in hu
Externí odkaz:
https://doaj.org/article/930f60a8a56f41d685369c49147e4604
Autor:
Neeltje van Doremalen, Jonathan E. Schulz, Danielle R. Adney, Taylor A. Saturday, Robert J. Fischer, Claude Kwe Yinda, Nazia Thakur, Joseph Newman, Marta Ulaszewska, Sandra Belij-Rammerstorfer, Greg Saturday, Alexandra J. Spencer, Dalan Bailey, Colin A. Russell, Sarah C. Gilbert, Teresa Lambe, Vincent J. Munster
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-12 (2022)
Whilst the ChAdOx1 nCoV-19 (AZD1222) vaccine has demonstrated efficacy against symptomatic disease, variants of concern (VOCs) with spike protein substitutions have led researchers to explore updating vaccines from ancestral spike protein. Authors us
Externí odkaz:
https://doaj.org/article/31185d37259445658dbebb616238f453
Autor:
Sue Ann Costa Clemens, Pedro M. Folegatti, Katherine R. W. Emary, Lily Yin Weckx, Jeremy Ratcliff, Sagida Bibi, Ana Verena De Almeida Mendes, Eveline Pipolo Milan, Ana Pittella, Alexandre V. Schwarzbold, Eduardo Sprinz, Parvinder K. Aley, David Bonsall, Christophe Fraser, Michelle Fuskova, Sarah C. Gilbert, Daniel Jenkin, Sarah Kelly, Simon Kerridge, Teresa Lambe, Natalie G. Marchevsky, Yama F. Mujadidi, Emma Plested, Maheshi N. Ramasamy, Peter Simmonds, Tanya Golubchik, Merryn Voysey, Andrew J. Pollard, the AMPHEUS Project, Oxford COVID Vaccine Trial Team
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-10 (2021)
Emerging variants of SARS-CoV-2 raise concerns about vaccine efficiency. Here, the authors present a post-hoc analysis for the ChAdOx1 nCoV-19 (AZD1222) vaccine trial in Brazil and provide efficacy against symptomatic COVID-19 caused by the Zeta (P.2
Externí odkaz:
https://doaj.org/article/2174b542d59f4531bfbfd908fa719572
Autor:
Robert J. Fischer, Neeltje van Doremalen, Danielle R. Adney, Claude Kwe Yinda, Julia R. Port, Myndi G. Holbrook, Jonathan E. Schulz, Brandi N. Williamson, Tina Thomas, Kent Barbian, Sarah L. Anzick, Stacy Ricklefs, Brian J. Smith, Dan Long, Craig Martens, Greg Saturday, Emmie de Wit, Sarah C. Gilbert, Teresa Lambe, Vincent J. Munster
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Emerging SARS-CoV-2 variants raise concerns about vaccine effectiveness. Here, the authors show that the ChAdOx1 nCoV-19 (AZD1222) vaccine protects Syrian hamsters from pulmonary infection and disease after infection with SARS-CoV-2 B.1.351 or B.1.1.
Externí odkaz:
https://doaj.org/article/cd521c32186f4059b6298768dcc0d51a
Autor:
Teresa Lambe, Alexandra J. Spencer, Kelly M. Thomas, Karen E. Gooch, Stephen Thomas, Andrew D. White, Holly E. Humphries, Daniel Wright, Sandra Belij-Rammerstorfer, Nazia Thakur, Carina Conceicao, Robert Watson, Leonie Alden, Lauren Allen, Marilyn Aram, Kevin R. Bewley, Emily Brunt, Phillip Brown, Breeze E. Cavell, Rebecca Cobb, Susan A. Fotheringham, Ciaran Gilbride, Debbie J. Harris, Catherine M. K. Ho, Laura Hunter, Chelsea L. Kennard, Stephanie Leung, Vanessa Lucas, Didier Ngabo, Kathryn A. Ryan, Hannah Sharpe, Charlotte Sarfas, Laura Sibley, Gillian S. Slack, Marta Ulaszewska, Nadina Wand, Nathan R. Wiblin, Fergus V. Gleeson, Dalan Bailey, Sally Sharpe, Sue Charlton, Francisco J. Salguero, Miles W. Carroll, Sarah C. Gilbert
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-12 (2021)
Lambe, Spencer, Thomas, Gilbert and colleagues report on the detailed immune profile of rhesus macaques and ferrets vaccinated against SARS-CoV-2 under high dose challenge. Their findings indicate that the ChAdOx1 nCoV-19 (AZD1222) the vaccine induce
Externí odkaz:
https://doaj.org/article/9f8c33e0c50a4a85acb2b5617681d0f4
Autor:
Alexandra J. Spencer, Paul F. McKay, Sandra Belij-Rammerstorfer, Marta Ulaszewska, Cameron D. Bissett, Kai Hu, Karnyart Samnuan, Anna K. Blakney, Daniel Wright, Hannah R. Sharpe, Ciaran Gilbride, Adam Truby, Elizabeth R. Allen, Sarah C. Gilbert, Robin J. Shattock, Teresa Lambe
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-8 (2021)
Heterologous vaccination regimens for COVID-19 could be useful for example if there is a shortage of one vaccine type. Here, Spencer et al. show that heterologous vaccination with a self-amplifying RNA vaccine and an adenoviral vectored vaccine perfo
Externí odkaz:
https://doaj.org/article/b9635c93599e4d14abcf385c2298f08d
Autor:
Glenn A. Marsh, Alexander J. McAuley, Gough G. Au, Sarah Riddell, Daniel Layton, Nagendrakumar B. Singanallur, Rachel Layton, Jean Payne, Peter A. Durr, Hannah Bender, Jennifer A. Barr, John Bingham, Victoria Boyd, Sheree Brown, Matthew P. Bruce, Kathie Burkett, Teresa Eastwood, Sarah Edwards, Tamara Gough, Kim Halpin, Jenni Harper, Clare Holmes, William S. J. Horman, Petrus Jansen van Vuren, Suzanne Lowther, Kate Maynard, Kristen D. McAuley, Matthew J. Neave, Timothy Poole, Christina Rootes, Brenton Rowe, Elisha Soldani, Vittoria Stevens, Cameron R. Stewart, Willy W. Suen, Mary Tachedjian, Shawn Todd, Lee Trinidad, Duane Walter, Naomi Watson, Trevor W. Drew, Sarah C. Gilbert, Teresa Lambe, S. S. Vasan
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-8 (2021)
Abstract Vaccines against SARS-CoV-2 are likely to be critical in the management of the ongoing pandemic. A number of candidates are in Phase III human clinical trials, including ChAdOx1 nCoV-19 (AZD1222), a replication-deficient chimpanzee adenoviru
Externí odkaz:
https://doaj.org/article/50b66ce00589424eb554445061a67484